Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

KYMR

Kymera Therapeutics Inc

119.35

Jul 10 • 04:00PM ET +0.35 (0.29%)

Healthcare Biotechnology USA Mid NASD

Peers: BMRN INCY KRYS NUVL AXSM CYTK MDGL VKTX KROS NBIX

| Held by: IWM VTI XBI VB VBK IBB IWO VXF SCHA VTWO

Scroll to Statements

Index	RUT
Market Cap	9.82B
Enterprise Value	9.25B
Income	-315.00M
Sales	51.48M
Book/sh	18.73
Cash/sh	7.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	238
IPO	Aug 21, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	190.70
P/B	6.37
P/C	15.08
P/FCF	-
EV/EBITDA	-
EV/Sales	179.62
Quick Ratio	10.81
Current Ratio	10.81
Debt/Eq	0.05
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-3.57
EPS next Y	-4.29
EPS next Q	-0.73
EPS this Y	5.82%
EPS next Y	-23.48%
EPS next 5Y	-8.26%
EPS past 3/5Y	-8.68% -3.19%
Sales past 3/5Y	-5.74% 2.87%
EPS Y/Y TTM	-15.21%
Sales Y/Y TTM	-12.58%
EPS Q/Q	13.26%
Sales Q/Q	55.50%
Earnings	Apr 30 BMO
EPS/Sales Surpr.	19.36% 315.71%

Insider Own	11.30%
Insider Trans	-30.08%
Inst Own	103.49%
Inst Trans	4.13%
ROA	-24.35%
ROE	-27.09%
ROIC	-19.61%
Gross Margin	83.90%
Oper. Margin	-690.19%
Profit Margin	-611.96%
SMA20	14.60%
SMA50	32.80%
SMA200	52.80%
Trades

Shs Outstand	82.18M
Shs Float	72.97M
Short Float	13.90%
Short Ratio	13.00
Short Interest	10.15M
52W High	130.05 -8.23%
52W Low	36.65 225.65%
Volatility	5.26% 6.97%
ATR (14)	6.55
RSI (14)	70.79
Beta	1.94
Rel Volume	0.85
Avg Volume	780.45K
Volume	665,428

Perf Week	5.14%
Perf Month	55.18%
Perf Quarter	36.63%
Perf Half Y	55.63%
Perf YTD	53.39%
Perf Year	163.99%
Perf 3Y	435.44%
Perf 5Y	126.17%
Perf 10Y	-
Recom	1.13
Target Price	123.76
Prev Close	119.00
Price	119.35
Change	0.29%

Date	Action	Analyst	Rating Change	Price Target Change
May-06-26	Initiated	Canaccord Genuity	Buy	$106
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Resumed	Barclays	Overweight	$133
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-03-25	Resumed	Guggenheim	Buy	$90
Oct-24-25	Reiterated	B. Riley Securities	Buy	$60 → $80
Oct-21-25	Initiated	Mizuho	Outperform	$81
Sep-18-25	Reiterated	H.C. Wainwright	Buy	$60 → $70
Sep-17-25	Initiated	Barclays	Overweight	$60
Sep-16-25	Initiated	RBC Capital Mkts	Outperform	$70
Jul-30-25	Resumed	B. Riley Securities	Buy	$60
Jul-03-25	Resumed	Morgan Stanley	Overweight	$70
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$79
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy	$60
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy	$51
May-20-25	Resumed	Stifel	Buy	$55
Mar-13-25	Initiated	Citigroup	Buy	$52
Dec-10-24	Initiated	BTIG Research	Buy	$60
Dec-06-24	Initiated	BMO Capital Markets	Market Perform	$55
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$57

Show Previous Ratings

Jul-07-26 07:00AM	Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Jul-03-26 04:00AM	Alkami Technology, Diebold Nixdorf, and 3 More Stocks See Action From Activist Investors. (Barrons.com)
Jun-25-26 07:58PM	KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline (Stocktwits) +16.61% -7.16%
11:16AM	Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi? (Investor's Business Daily)
07:00AM	Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 (GlobeNewswire)
04:01PM	Loading…
Jun-24-26 04:01PM	Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors (GlobeNewswire)
Jun-12-26 07:00AM	Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting (GlobeNewswire)
Jun-09-26 07:00AM	Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration (GlobeNewswire)
Jun-08-26 04:01PM	Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations (GlobeNewswire)
07:00AM	Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses (GlobeNewswire)
May-27-26 07:00AM	Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-26 07:00AM	Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses (GlobeNewswire)
May-06-26 09:38AM	AMD upgraded, Reddit downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Kymera Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-05-26 07:00AM	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week (GlobeNewswire)
07:00AM	Loading…
Apr-30-26 07:00AM	Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-29-26 09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q1 2026 Result (GuruFocus.com)
Apr-23-26 07:00AM	Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 (GlobeNewswire)
Apr-13-26 07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma (GlobeNewswire)
Apr-09-26 07:00AM	Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate (GlobeNewswire)
Mar-28-26 11:00AM	Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-10-26 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-09-26 10:38PM	Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss (24/7 Wall St.)
Feb-28-26 01:32PM	Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 (MarketBeat)
Feb-27-26 09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
09:00AM	Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler (TipRanks)
Feb-26-26 05:03PM	Kymera Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:08PM	Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
09:55AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-26 07:19AM	Kymera Therapeutics Inc (KYMR) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-26 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-19-26 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-14-26 01:03AM	Kymera Therapeutics Touts Once-Daily Oral Biologics-Like KT-621 at Guggenheim Conference (MarketBeat)
Feb-04-26 07:00AM	Kymera Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-30-26 10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Jan-15-26 11:35AM	Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside (Insider Monkey) -5.44%
Jan-13-26 07:00AM	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire)
Jan-12-26 12:00PM	Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why (Zacks)
Jan-06-26 07:00AM	Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Jan-05-26 01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
Jan-01-26 11:35AM	Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks (MarketBeat)
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 09:45AM	Share Offerings Prompt Huge Insider Buying in These 3 Biotechs (24/7 Wall St.)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-12-25 10:30AM	Kymera's Eczema Drug Gets Fast Track Designation in the United States (Zacks)
Dec-11-25 04:01PM	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis (GlobeNewswire)
Dec-09-25 11:30PM	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering (GlobeNewswire) -7.87%
02:23PM	Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress (Insider Monkey)
10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
Dec-08-25 04:09PM	Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? (Investor's Business Daily) +41.55%
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:10PM	This Drugmaker's Stock Is Soaring Over 40% Monday (Investopedia)
01:07PM	Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:42AM	Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-05-25 04:01PM	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 (GlobeNewswire)
11:30AM	Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? (Zacks)
Dec-04-25 11:30AM	Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 07:33AM	Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
Nov-25-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Nov-24-25 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-04-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-03-25 07:26AM	Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-28-25 07:00AM	Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-27-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting (GlobeNewswire)
Oct-23-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-01-25 09:38AM	Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline (Zacks)
Sep-17-25 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses (GlobeNewswire)
Sep-16-25 12:30PM	Kymera initiated at Outperform on potential of lead skin drug (Investing.com)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-07-25 10:08AM	Why Kymera (KYMR) Could Be One of Biotech's Most Interesting Growth Stories? (Insider Monkey)
Sep-03-25 07:00AM	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary (GlobeNewswire) +6.41%
Aug-27-25 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-25 03:04AM	Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com) +5.81%
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.24%
07:00AM	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-25 09:23AM	GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up (Zacks)
09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result (GuruFocus.com)
Aug-06-25 10:00AM	CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Aug-04-25 07:00AM	Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-30-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 09:54AM	Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating (Insider Monkey)
Jul-09-25 06:02AM	Morgan Stanley Puts These 2 Stocks on Its Buy List Heres Why You Should Follow (TipRanks)
Jun-30-25 09:32AM	NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
Jun-28-25 04:16AM	Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer (Insider Monkey)
Jun-27-25 10:19AM	Kymeras partnerships with Sanofi and Gilead drive value (Investing.com)
Jun-26-25 11:56PM	Kymera Therapeutics Announces Pricing of $250 Million Public Offering (GlobeNewswire)
10:45AM	Kymera weakness a buying opportunity, says Stifel (TipRanks)
09:06AM	Morning Movers: General Mills dips following fourth quarter report (TipRanks)
08:40AM	KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update (Zacks)
Jun-25-25 04:05PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Ph.D.Dr. Nello Mainolfi M.D.

Chief Financial OfficerMr. Bruce N. Jacobs CFA

Chief Legal Officer & Corporate SecretaryMr. Brian R. Adams J.D.

Chief Medical OfficerDr. Jared A. Gollob M.D.

Chief Business OfficerMr. Noah Goodman M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mainolfi Nello	Chief Executive Officer	Jul 07 '26	Option Exercise	2.08	50,000	104,000	716,568	Jul 07 08:00 PM
Mainolfi Nello	Chief Executive Officer	Jul 07 '26	Sale	119.00	50,000	5,950,000	666,568	Jul 07 08:00 PM
Mainolfi Nello	Officer	Jul 07 '26	Proposed Sale	119.00	50,000	5,950,000		Jul 07 04:07 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 30 '26	Option Exercise	5.33	61,378	327,145	321,992	Jul 02 06:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 30 '26	Sale	114.96	77,109	8,864,829	244,883	Jul 02 06:30 PM
Goodman Noah	Chief Business Officer	Jul 01 '26	Sale	114.29	3,389	387,329	47,179	Jul 02 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '26	Option Exercise	2.08	80,000	166,400	746,568	Jul 02 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '26	Sale	115.29	80,000	9,223,527	666,568	Jul 02 06:30 PM
Mainolfi Nello	Officer	Jul 01 '26	Proposed Sale	114.29	80,000	9,143,200		Jul 02 08:33 AM
NOAH GOODMAN	Officer	Jul 01 '26	Proposed Sale	114.67	3,389	388,617		Jul 01 04:58 PM
Booth Bruce	Director	Jun 29 '26	Sale	109.48	31,283	3,424,800	461,794	Jun 30 05:32 PM
Booth Bruce	Director	Jun 26 '26	Sale	110.29	467,878	51,603,032	472,267	Jun 30 05:30 PM
Booth Bruce	Director	Jun 29 '26	Sale	107.06	45,367	4,857,104	466,077	Jun 30 05:30 PM
BRUCE N. JACOBS	Officer	Jun 30 '26	Proposed Sale	109.32	77,109	8,429,556		Jun 30 04:32 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 29 '26	Proposed Sale	108.12	10,473	1,132,341		Jun 29 05:51 PM
Atlas Venture Fund X, LP	Shareholder	Jun 29 '26	Proposed Sale	108.12	66,177	7,155,057		Jun 29 05:51 PM
BVF PARTNERS L P/IL	Director	Jun 26 '26	Sale	106.50	1,578,800	168,142,200	240,123	Jun 26 06:48 PM
BVF PARTNERS L P/IL	Director	Jun 26 '26	Sale	106.50	51,858	5,522,877	78,787	Jun 26 06:48 PM
BVF PARTNERS L P/IL	Affiliate of Director	Jun 26 '26	Proposed Sale	116.46	1,630,658	189,906,431		Jun 26 06:13 PM
Atlas Venture Fund X, LP	Shareholder	Jun 26 '26	Proposed Sale	116.46	410,427	47,798,328		Jun 26 04:52 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 26 '26	Proposed Sale	116.46	57,451	6,690,743		Jun 26 04:51 PM
Booth Bruce	Director	Jun 25 '26	Sale	121.86	285,684	34,812,909	529,718	Jun 25 09:56 PM
Booth Bruce	Director	Jun 25 '26	Sale	115.39	262,637	30,306,107	564,668	Jun 25 09:55 PM
Booth Bruce	Director	Jun 24 '26	Sale	100.51	134,720	13,540,476	597,047	Jun 25 09:55 PM
Booth Bruce	Director	Jun 23 '26	Sale	99.98	1,408	140,772	613,589	Jun 25 09:55 PM
Goodman Noah	Chief Business Officer	Jun 25 '26	Option Exercise	21.05	5,000	105,250	55,195	Jun 25 06:00 PM
Goodman Noah	Chief Business Officer	Jun 25 '26	Sale	114.00	5,000	570,000	50,195	Jun 25 06:00 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 25 '26	Proposed Sale	99.87	67,329	6,724,147		Jun 25 05:26 PM
Atlas Venture Fund X, LP	Shareholder	Jun 25 '26	Proposed Sale	99.87	480,992	48,036,671		Jun 25 05:25 PM
NOAH GOODMAN	Officer	Jun 25 '26	Proposed Sale	99.87	5,000	499,350		Jun 25 04:27 PM
Atlas Venture Fund X, LP	Shareholder	Jun 24 '26	Proposed Sale	98.25	118,178	11,610,988		Jun 24 05:30 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 24 '26	Proposed Sale	98.25	16,542	1,625,252		Jun 24 05:29 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 23 '26	Proposed Sale	99.45	173	17,205		Jun 23 06:14 PM
Atlas Venture Fund X, LP	Shareholder	Jun 23 '26	Proposed Sale	99.45	1,235	122,821		Jun 23 06:14 PM
Booth Bruce	Director	Jun 22 '26	Sale	103.75	31,798	3,299,037	613,762	Jun 22 09:02 PM
Booth Bruce	Director	Jun 17 '26	Option Exercise	20.00	11,741	234,820	11,741	Jun 22 09:01 PM
Booth Bruce	Director	Jun 22 '26	Sale	98.52	246,330	24,268,861	617,663	Jun 22 09:01 PM
Booth Bruce	Director	Jun 18 '26	Sale	91.01	115,056	10,471,661	647,914	Jun 22 09:01 PM
Booth Bruce	Director	Jun 17 '26	Sale	90.38	105,071	9,496,317	662,042	Jun 22 09:01 PM
Booth Bruce	Director	Jun 17 '26	Sale	89.98	11,741	1,056,455	0	Jun 22 09:01 PM
Goodman Noah	Chief Business Officer	Jun 22 '26	Option Exercise	21.05	2,500	52,625	52,695	Jun 22 05:47 PM
Goodman Noah	Chief Business Officer	Jun 22 '26	Sale	99.00	2,500	247,500	50,195	Jun 22 05:47 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 22 '26	Proposed Sale	90.43	34,152	3,088,365		Jun 22 05:28 PM
Atlas Venture Fund X, LP	Shareholder	Jun 22 '26	Proposed Sale	90.43	243,976	22,062,750		Jun 22 05:28 PM
NOAH GOODMAN	Officer	Jun 22 '26	Proposed Sale	90.43	2,500	226,075		Jun 22 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 18 '26	Proposed Sale	89.90	14,128	1,270,107		Jun 18 05:35 PM
Atlas Venture Fund X, LP	Shareholder	Jun 18 '26	Proposed Sale	89.90	100,928	9,073,427		Jun 18 05:35 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 17 '26	Proposed Sale	87.44	12,902	1,128,151		Jun 17 05:26 PM
Atlas Venture Fund X, LP	Shareholder	Jun 17 '26	Proposed Sale	87.44	92,169	8,059,257		Jun 17 05:25 PM
Bruce Booth	Director	Jun 17 '26	Proposed Sale	87.44	11,741	1,026,633		Jun 17 05:25 PM
JEREMY CHADWICK	Officer	Jun 17 '26	Proposed Sale	87.44	66,893	5,849,124		Jun 17 04:43 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 02 '26	Option Exercise	2.08	12,653	26,318	260,241	Jun 03 07:30 AM
Chadwick Jeremy G	Chief Operating Officer	May 26 '26	Sale	79.36	12,905	1,024,194	48,297	May 27 05:50 PM
Chadwick Jeremy G	Chief Operating Officer	May 27 '26	Sale	81.58	4,279	349,096	44,018	May 27 05:50 PM
JEREMY CHADWICK	Officer	May 26 '26	Proposed Sale	78.89	13,130	1,035,826		May 26 04:41 PM
Chadwick Jeremy G	Officer	May 26 '26	Proposed Sale	78.42	4,054	317,922		May 26 04:01 PM
Esposito Pamela	Director	May 19 '26	Option Exercise	31.20	1,000	31,200	1,000	May 19 04:05 PM
Jacobs Bruce N.	Chief Financial Officer	May 18 '26	Option Exercise	2.08	15,000	31,200	247,588	May 19 07:30 AM
Ridloff Elena	Director	May 11 '26	Option Exercise	31.20	3,000	93,600	3,000	May 11 04:58 PM
Ridloff Elena	Director	May 11 '26	Sale	87.00	3,000	261,000	0	May 11 04:58 PM
ELENA RIDLOFF	Director	May 11 '26	Proposed Sale	86.08	3,000	258,240		May 11 04:35 PM
Mainolfi Nello	Chief Executive Officer	Apr 29 '26	Option Exercise	2.08	30,000	62,400	696,195	Apr 29 05:00 PM
Mainolfi Nello	Chief Executive Officer	Apr 29 '26	Sale	81.18	30,000	2,435,377	666,195	Apr 29 05:00 PM
Mainolfi Nello	Officer	Apr 29 '26	Proposed Sale	82.47	30,000	2,474,100		Apr 29 04:07 PM
Booth Bruce	Director	Apr 22 '26	Option Exercise	14.44	5,900	85,169	5,900	Apr 24 04:33 PM
Booth Bruce	Director	Apr 22 '26	Sale	89.96	5,900	530,764	0	Apr 24 04:33 PM
Booth Bruce	Director	Apr 22 '26	Sale	90.08	100	9,008	674,944	Apr 24 04:33 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 22 '26	Option Exercise	39.06	300	11,717	61,502	Apr 24 04:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 22 '26	Sale	90.00	300	27,000	61,202	Apr 24 04:30 PM
Atlas Venture Fund X, LP	Shareholder	Apr 22 '26	Proposed Sale	88.07	88	7,750		Apr 22 04:52 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 22 '26	Proposed Sale	88.07	12	1,057		Apr 22 04:52 PM
JEREMY CHADWICK	Officer	Apr 22 '26	Proposed Sale	88.07	300	26,421		Apr 22 04:30 PM
Goodman Noah	Chief Business Officer	Apr 14 '26	Sale	90.00	1,347	121,230	50,195	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 14 '26	Option Exercise	32.16	5,251	168,887	66,453	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 15 '26	Option Exercise	43.50	1,300	56,550	62,502	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 14 '26	Sale	90.00	5,251	472,598	61,202	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 15 '26	Sale	90.00	1,300	117,000	61,202	Apr 16 06:30 PM
Booth Bruce	Director	Apr 14 '26	Option Exercise	14.18	4,159	58,975	4,159	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Option Exercise	14.18	2,200	31,196	2,200	Apr 16 06:16 PM
Booth Bruce	Director	Apr 14 '26	Sale	89.97	4,159	374,185	0	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Sale	90.10	3,135	282,464	674,956	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Sale	89.95	2,200	197,890	0	Apr 16 06:16 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 15 '26	Proposed Sale	89.87	385	34,600		Apr 15 04:51 PM
Atlas Venture Fund X, LP	Shareholder	Apr 15 '26	Proposed Sale	89.87	2,750	247,142		Apr 15 04:51 PM
JEREMY CHADWICK	Officer	Apr 15 '26	Proposed Sale	89.86	1,300	116,824		Apr 15 04:41 PM
Bruce Booth	Director	Apr 14 '26	Proposed Sale	88.53	24,000	2,124,720		Apr 14 05:19 PM
JEREMY CHADWICK	Officer	Apr 14 '26	Proposed Sale	88.53	5,251	464,871		Apr 14 04:37 PM
Goodman Noah	Chief Business Officer	Apr 09 '26	Option Exercise	21.05	2,500	52,625	61,806	Apr 10 04:45 PM
Goodman Noah	Chief Business Officer	Apr 09 '26	Sale	87.50	8,264	723,082	53,542	Apr 10 04:45 PM
Goodman Noah	Chief Business Officer	Apr 10 '26	Sale	87.35	2,000	174,700	51,542	Apr 10 04:45 PM
Noah Goodman	Officer	Apr 09 '26	Proposed Sale	87.35	11,611	1,014,221		Apr 09 04:28 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 01 '26	Option Exercise	29.64	14,640	433,930	75,842	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 31 '26	Option Exercise	29.64	7,600	225,264	68,802	Apr 01 07:00 PM
Ridloff Elena	Director	Mar 31 '26	Option Exercise	14.18	7,400	104,932	7,400	Apr 01 07:00 PM
Ridloff Elena	Director	Apr 01 '26	Option Exercise	14.18	4,600	65,228	4,600	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 01 '26	Sale	85.46	14,640	1,251,166	61,202	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 31 '26	Sale	85.38	7,600	648,882	61,202	Apr 01 07:00 PM
Ridloff Elena	Director	Mar 31 '26	Sale	85.37	7,400	631,739	0	Apr 01 07:00 PM
Ridloff Elena	Director	Apr 01 '26	Sale	85.42	4,600	392,922	0	Apr 01 07:00 PM
ELENA RIDLOFF	Director	Apr 01 '26	Proposed Sale	83.29	4,600	383,134		Apr 01 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYMR

Kymera Therapeutics Inc

Upgrade your Finviz experience